Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Fidaxomicin tablets launched for Clostridium difficile

By News team

Fidaxomicin tablets have been launched for the treatment of adults infected with Clostridium difficile.

Marketed by Astellas under the brand name Dificlir, the 200mg tablets are given twice daily for 10 days, with or without food. The drug has no contraindications, other than hypersensitivity, but should be used with caution in patients with severe kidney impairment, moderate-to-severe liver impairment, pseudomembranous colitis, and fulminant or life-threatening C difficile infection.

Caution is also advised when treating patients with inflammatory bowel disease, because of the risk of enhanced absorption and systemic adverse reactions.

Fidaxomicin is a substrate of P-glycoprotein and may be a mild-to-moderate inhibitor of the transporter protein in the intestine, the summary of product characteristics says.

Product information

Class: Macrocyclic antibacterial

Dose: 200mg twice daily

NHS list price: 20 x 200mg film-coated tablets, £1,350.00

Legal category: POM

In clinical trials, patients’ fidaxomicin exposure increased when the drug was co-administered with another P-glycoprotein inhibitor. Because the clinical relevance of this increase is unclear, fidaxomicin should not be co-administered with potent P-glycoprotein inhibitors, such as cyclosporine, ketoconazole, erythromycin, clarithromycin, verapamil, dronedarone and amiodarone.

Studies suggest that fidaxomicin treatment does not affect patients’ normal intestinal flora.

Citation: The Pharmaceutical Journal URI: 11102560

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Dificlir pack shot

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.